Loading
Supportive care began as the drugs that let people get through chemotherapy. It is now a discipline with randomised proof that exercise, early palliative care and symptom monitoring lengthen life, and its next task is organised lifelong care for the growing population of people living after cancer.
Modern chemotherapy was made deliverable by supportive care: 5-HT3 antiemetics, growth factors that prevent febrile neutropenia, implanted ports and structured pain management. The second phase recognised what cure costs. The Childhood Cancer Survivor Study, running since 1994, catalogued heart damage, infertility, second cancers and cognitive effects decades after treatment, and cardio-oncology, oncofertility and survivorship care plans grew out of it.
The third phase, now under way, is evidence that supportive interventions change hard outcomes. Early integrated palliative care, electronic symptom monitoring and geriatric assessment have each improved survival or reduced toxicity in randomised trials, and in 2025 the CHALLENGE trial showed that a coached exercise programme after colon cancer treatment reduces recurrence and death. Cheap fixes with strong evidence (scalp cooling, low-dose olanzapine, sodium thiosulfate for cisplatin hearing loss) are spreading unevenly. Cachexia, which has never had an approved drug in most countries, has its first candidate in GDF-15 blockade.
The pace is set by funding and organisation rather than science: survivorship research has no industry sponsor, late effects are not systematically recorded, and follow-up is delivered by whoever has capacity rather than by risk.
Curative regimens depended on drugs and devices that never made a headline: 5-HT3 antiemetics replaced days of vomiting, G-CSF let full doses be given on schedule by preventing febrile neutropenia, implanted ports and ambulatory pumps moved infusions out of hospital, and the WHO analgesic ladder made cancer pain a treatable problem. Hospice and palliative medicine became specialties in the same years.
The Childhood Cancer Survivor Study, following tens of thousands of people cured as children, showed that anthracyclines, chest radiation and alkylators leave heart failure, second cancers and infertility decades later, and produced the first risk-based follow-up guidelines. Cardio-oncology, oncofertility and survivorship care plans grew from this evidence; dexrazoxane was shown to protect the heart from anthracyclines.
Randomised trials moved supportive care from kindness to treatment. Early integrated palliative care improved quality of life and, in some trials, survival; weekly electronic symptom reporting with nurse response reduced emergency visits and extended survival; geriatric assessment before chemotherapy cut severe toxicity in older patients. In 2025 CHALLENGE showed that a three-year coached exercise programme after colon cancer treatment reduces recurrence and improves survival, and PREHAB showed that four weeks of training before colorectal surgery cuts complications.
Scalp cooling preserves hair through chemotherapy, sodium thiosulfate halves permanent hearing loss from cisplatin in children, a 2.5 mg dose of olanzapine restores appetite and weight for pennies (Tata Memorial), acupuncture eases hot flushes and aromatase inhibitor joint pain, cognitive behavioural therapy treats the insomnia that persists for years, and compression and exercise reverse early lymphoedema. Each is proven; none is universally offered.
Wasting kills many patients with advanced cancer and stops many more from tolerating treatment, and no drug has been approved for it in most of the world. Ponsegromab, an antibody that blocks GDF-15, the hormone that drives much of the wasting, improved weight and activity in phase 2; anamorelin is licensed only in Japan; resistance training and protein remain the only widely available intervention. A physical-function endpoint that regulators accept is the gating step for approval.
Tens of millions of people live after cancer, and follow-up is still organised by habit. The system being built: risk-stratified follow-up with low-risk survivors in primary care and fast re-entry, survivorship plans generated automatically from the treatment record, late-effects registries that link exposures to outcomes decades later, biomarker-guided cardioprotection for everyone on cardiotoxic therapy, screening for financial toxicity as a vital sign, and vocational rehabilitation so people can return to work.
A survivor biobank could show who will develop heart failure or a second cancer before they do; an open commons of patient-reported outcome data from trials would let side-effects be compared across drugs the way efficacy is; exercise could be dosed like a drug once dose-finding trials exist; and chemotherapy-induced neuropathy, still without a proven prevention, has candidates in SARM1 inhibitors and limb cooling. An ARPA-style programme for supportive-care drugs that no company will develop is the funding proposal that would make most of this happen.
Supportive care has no patent to protect, so its trials are publicly funded or not run. Late effects are not systematically recorded, so their scale is estimated rather than known. Toxicity and quality of life are measured less rigorously than survival in registrational trials. And most people who die of cancer worldwide do so without adequate pain relief. A survivorship research endowment funded by a levy on curative therapies is one proposal to fix the first problem.
Every era's records, trial outcomes and papers, and every watch item, as JSON.
Probability ranges are named estimates that the claim is borne out on roughly a five-year horizon. They are meant to be argued with: propose a revision with your name and reasoning via a pull request to src/data/confidence.ts.
Loading this step…
Loading this step…
Loading this step…
Loading this step…
Loading this step…
Loading this step…
Loading this step…
Loading this step…
For colon cancer survivors, a prescribed, supported exercise programme is now an evidence-based treatment with a survival benefit comparable to many drugs. Health systems will need to fund exercise consultants as they fund chemotherapy. The trial does not tell us whether unsupervised advice achieves the same.
The first drug to reverse cancer cachexia mechanistically rather than by appetite stimulation, in a disease where weight loss stops chemotherapy being delivered; the phase 3 programme and the question of survival remain.
Shares A survivorship research endowment funded by a levy on curative therapy prices, A dedicated programme for cachexia and treatment toxicity research, A dose-finding trial for exercise after cancer, CHALLENGE: a structured exercise programme after chemotherapy improves survival in colon cancer.
Shares A dose-finding trial for exercise after cancer, CHALLENGE: a structured exercise programme after chemotherapy improves survival in colon cancer, CHALLENGE (CCTG CO.21), Structured exercise programmes after curative treatment.
Shares ROMANA 1 and ROMANA 2, Ponsegromab phase 2 in cancer cachexia, Cachexia-directed therapy (GDF-15 blockade), Resistance training and protein for cachexia and sarcopenia.
Shares A prevention programme for chemotherapy nerve damage: SARM1 inhibitors, cooling and compression, Infusion pumps, ports, and ambulatory chemotherapy devices, Dexrazoxane, Sodium thiosulfate (otoprotectant).
Shares Ponsegromab phase 2 in cancer cachexia, CHALLENGE: a structured exercise programme after chemotherapy improves survival in colon cancer, Resistance training and protein for cachexia and sarcopenia, Cachexia, toxicity and the limits of the patient.
Shares ROMANA 1 and ROMANA 2, Ponsegromab phase 2 in cancer cachexia, Resistance training and protein for cachexia and sarcopenia, Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine.
Shares Biomarker-guided cardioprotection for everyone on cardiotoxic cancer therapy, Dexrazoxane, Late deaths after childhood cancer, what causes them, and the proof that gentler treatment worked, Childhood Cancer Survivor Study (CCSS).
Shares Cachexia-directed therapy (GDF-15 blockade), Resistance training and protein for cachexia and sarcopenia, Prehabilitation before cancer surgery, Nutrition support and cachexia management.